Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 9;17(8):1470–1486. doi: 10.1074/mcp.RA118.000633

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Nguyen et al.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Fig. 8. — Identification of potential mechanisms of sensitivity and resistance to 17-AAG treatment based on changes in protein expression in responders, poor responders, and non-responders. The plots indicate mean (± S.D.) of proteins that showed significant alteration upon treatment with 17-AAG (paired t test, *p value ≤0.01, **p value ≤0.001, ***p value ≤.0001). A, 17 proteins with increased expression upon 17-AAG treatment in validation cohort “Responder” PDE samples (n = 9). B, 4 proteins with decreased expression upon 17-AAG treatment in validation cohort “Responder” PDE samples (n = 9). C, 10 proteins with increased expression upon 17-AAG treatment in validation cohort “Non-responder” PDE samples (n = 12). D, 13 proteins with decreased expression upon 17-AAG treatment in validation cohort “Non-responder” PDE samples (n = 12). E, 9 proteins with increased expression upon 17-AAG treatment in Validation cohort “Poor responder” PDE samples (n = 4).